Eric A F SimÃues

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/281378/publications.pdf

Version: 2024-02-01

		186265	82547
77	8,068	28	72
papers	citations	h-index	g-index
79	79	79	7132
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Respiratory Syncytial Virus–Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 225, 1100-1111.	4.0	35
2	Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders. Journal of Infectious Diseases, 2022, 225, 578-586.	4.0	6
3	Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study. Open Forum Infectious Diseases, 2022, 9, ofac087.	0.9	10
4	Comparison of the medical burden of COVIDâ€19 with seasonal influenza and measles outbreaks. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 595-601.	1.5	0
5	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet, The, 2022, 399, 2047-2064.	13.7	445
6	Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. Clinical Infectious Diseases, 2021, 73, e4400-e4408.	5.8	77
7	Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. The Lancet Global Health, 2021, 9, e33-e43.	6.3	71
8	Single-dose nirsevimab prevents RSV infection. Journal of Pediatrics, 2021, 228, 310-313.	1.8	4
9	Reopening Schools and the Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Israel: A Nationwide Study. Clinical Infectious Diseases, 2021, 73, 2265-2275.	5.8	21
10	Population-based otoscopic and audiometric assessment of a birth cohort recruited for a pneumococcal vaccine trial 15–18 years earlier: a protocol. BMJ Open, 2021, 11, e042363.	1.9	0
11	Adult Population Coverage With Influenza Vaccine and Influenza Hospitalization Rates—Is There a Role for Active Outreach to Immunize At-Risk Neighborhoods?. Clinical Infectious Diseases, 2021, 73, 1110-1112.	5.8	1
12	Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel. JAMA Network Open, 2021, 4, e217105.	5.9	16
13	Intrafamilial Spread and Altered Symptomatology of SARS-CoV-2, During Predominant Circulation of Lineage B.1.1.7 Variant in Israel. Pediatric Infectious Disease Journal, 2021, 40, e310-e311.	2.0	10
14	Respiratory syncytial virus and influenza hospitalizations in Danish children 2010–2016. Vaccine, 2021, 39, 4126-4134.	3.8	8
15	Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e1077-e1087.	6.3	30
16	Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: A Prospective Community Cohort Study in Rural Maharashtra, India. Clinical Infectious Diseases, 2021, 73, S193-S202.	5.8	19
17	The Burden of Respiratory Syncytial Virus in Children Under 2 Years of Age in a Rural Community in Maharashtra, India. Clinical Infectious Diseases, 2021, 73, S238-S247.	5.8	8
18	Global Respiratory Syncytial Virus–Related Infant Community Deaths. Clinical Infectious Diseases, 2021, 73, S229-S237.	5.8	29

#	Article	IF	Citations
19	Characteristics of SARS-CoV-2 Infections in Israeli Children During the Circulation of Different SARS-CoV-2 Variants. JAMA Network Open, 2021, 4, e2124343.	5.9	19
20	Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants. Journal of Infectious Diseases, 2020, 221, 1256-1270.	4.0	19
21	SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. American Journal of Perinatology, 2020, 37, 421-429.	1.4	53
22	Stateâ€level estimates of excess hospitalizations and deaths associated with influenza. Influenza and Other Respiratory Viruses, 2020, 14, 111-121.	3.4	12
23	Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden. Influenza and Other Respiratory Viruses, 2020, 14, 615-621.	3.4	20
24	Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV, the, 2020, 7, e91-e103.	4.7	16
25	Intent to obtain pediatric influenza vaccine among mothers in four middle income countries. Vaccine, 2020, 38, 4325-4335.	3.8	13
26	Evaluation of rates of laboratory-confirmed influenza hospitalization in rural and urban census tracts over eight influenza seasons. Preventive Medicine, 2020, 139, 106184.	3.4	3
27	Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine, 2020, 38, 2435-2448.	3.8	54
28	1719. Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2020, 7, S843-S843.	0.9	0
29	Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. Vaccine, 2019, 37, 5397-5403.	3.8	7
30	Otitis media related hearing loss in Indonesian school children. International Journal of Pediatric Otorhinolaryngology, 2019, 125, 44-50.	1.0	13
31	Underdetection of laboratory-confirmed influenza-associated hospital admissions among infants: a multicentre, prospective study. The Lancet Child and Adolescent Health, 2019, 3, 781-794.	5.6	22
32	Economic-Burden Trajectories in Commercially Insured US Infants With Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2019, 221, 1244-1255.	4.0	13
33	Lay Field-worker–Led School Health Program for Primary Schools in Low- and Middle-Income Countries. Pediatrics, 2019, 143, .	2.1	9
34	Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2019, 37, 392-399.	3.8	2
35	Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infectious Diseases and Therapy, 2018, 7, 87-120.	4.0	112
36	A Child With Intermittent Headaches and Eosinophilic Meningitis. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 355-357.	1.3	4

#	Article	IF	CITATIONS
37	Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field. Viral Immunology, 2018, 31, 195-203.	1.3	40
38	Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles. Viral Immunology, 2018, 31, 133-141.	1.3	15
39	RSV prevention in infancy and asthma in later life. Lancet Respiratory Medicine, the, 2018, 6, e30.	10.7	4
40	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease. Infectious Diseases and Therapy, 2017, 6, 37-56.	4.0	48
41	Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 29-38.	5.6	140
42	The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood. Infectious Diseases and Therapy, 2017, 6, 173-197.	4.0	133
43	Demographic and ecological risk factors for human influenza A virus infections in rural Indonesia. Influenza and Other Respiratory Viruses, 2017, 11, 425-433.	3.4	5
44	Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet, The, 2017, 390, 946-958.	13.7	1,634
45	Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases. Infectious Diseases and Therapy, 2017, 6, 383-411.	4.0	60
46	Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods. BMC Infectious Diseases, 2017, 17, 222.	2.9	6
47	The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children. Journal of Infectious Diseases, 2017, 215, 1-3.	4.0	12
48	Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clinical Infectious Diseases, 2017, 64, 1773-1779.	5.8	12
49	Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation. PLoS ONE, 2016, 11, e0166226.	2.5	21
50	Duration of Infant Protection Against Influenza Illness Conferred by Maternal Immunization. JAMA Pediatrics, 2016, 170, 840.	6.2	99
51	WU and KI polyomavirus infections in Filipino children with lower respiratory tract disease. Journal of Clinical Virology, 2016, 82, 112-118.	3.1	18
52	Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries. Infectious Diseases and Therapy, 2016, 5, 271-298.	4.0	204
53	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease. Infectious Diseases and Therapy, 2016, 5, 453-471.	4.0	56
54	Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease. Infectious Diseases and Therapy, 2016, 5, 417-452.	4.0	64

#	Article	IF	CITATIONS
55	Motavizumab, RSV, and subsequent wheezing. Lancet Infectious Diseases, The, 2016, 16, 639-640.	9.1	5
56	Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age. Open Forum Infectious Diseases, 2016, 3, ofw163.	0.9	14
57	Comparison of microarray-predicted closest genomes to sequencing for poliovirus vaccine strain similarity and influenza A phylogeny. Diagnostic Microbiology and Infectious Disease, 2016, 84, 203-206.	1.8	0
58	Challenges in estimating RSV-associated mortality rates. Lancet Respiratory Medicine, the, 2016, 4, 345-347.	10.7	23
59	Otitis Media and Its Sequelae in Kenyan Schoolchildren. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 375-384.	1.3	18
60	Intensive Care Unit Admission Rates for Respiratory Syncytial Virus Infection as a Function of Age in Preterm Infants Born at 32–35-week Gestation and Not Receiving Immunoprophylaxis. Pediatric Infectious Disease Journal, 2015, 34, 331.	2.0	2
61	Clinical Endpoints for Respiratory Syncytial Virus Prophylaxis Trials in Infants and Children in High-income and Middle-income Countries. Pediatric Infectious Disease Journal, 2015, 34, 1086-1092.	2.0	14
62	Disease mapping for informing targeted health interventions: childhood pneumonia in Bohol, Philippines. Tropical Medicine and International Health, 2015, 20, 1525-1533.	2.3	7
63	Live attenuated influenza vaccine tetravalent: a clinical review. Expert Review of Vaccines, 2015, 14, 963-973.	4.4	9
64	Using Mathematical Transmission Modelling to Investigate Drivers of Respiratory Syncytial Virus Seasonality in Children in the Philippines. PLoS ONE, 2014, 9, e90094.	2.5	28
65	Pathogen Chip for Respiratory Tract Infections. Journal of Clinical Microbiology, 2013, 51, 945-953.	3.9	25
66	Clinical and Epidemiologic Features of Respiratory Syncytial Virus. Current Topics in Microbiology and Immunology, 2013, 372, 39-57.	1.1	131
67	Chronic Diseases, Chromosomal Abnormalities, and Congenital Malformations as Risk Factors for Respiratory Syncytial Virus Hospitalization: A Population-Based Cohort Study. Clinical Infectious Diseases, 2012, 54, 810-817.	5.8	128
68	Down Syndrome and Hospitalizations due to Respiratory Syncytial Virus: AÂPopulation-Based Study. Journal of Pediatrics, 2012, 160, 827-831.e1.	1.8	61
69	The Epidemiology of Respiratory Syncytial Virus Lower Respiratory Tract Infections in Children Less than 5 Years of Age in Indonesia. Pediatric Infectious Disease Journal, 2011, 30, 778-784.	2.0	41
70	The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. Journal of Allergy and Clinical Immunology, 2010, 126, 256-262.	2.9	195
71	Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, The, 2010, 375, 1545-1555.	13.7	2,308
72	Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. Journal of Allergy and Clinical Immunology, 2009, 123, 398-403.	2.9	110

Eric A F Simões

#	Article	IF	CITATIONS
73	Respiratory syncytial virus infection: denominator-based studies in Indonesia, Mozambique, Nigeria and South Africa. Bulletin of the World Health Organization, 2004, 82, 914-22.	3.3	81
74	Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatric Infectious Disease Journal, 2003, 22, S21-S32.	2.0	212
75	Palivizumab. Drugs, 1999, 58, 312-313.	10.9	0
76	Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children. New England Journal of Medicine, 1993, 329, 1524-1530.	27.0	748
77	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. Journal of Infectious Diseases, 0, , .	4.0	8